SLC6A9: A Potential Drug Target and Biomarker for Neurotransmitter Transporter

Target Name: SLC6A9

NCBI ID: G6536

SLC6A9

SLC6A9: A Potential Drug Target and Biomarker for Neurotransmitter Transporter

Sodium channel subfamily A (SLC6A9) is a family of transmembrane proteins that play a crucial role in neurotransmitter transport and regulation. The SLC6A9 gene is located on chromosome 6 and encodes for a protein that is expressed in various tissues and cell types, including brain, heart, and pancreas. The protein is a member of the solute carrier family 6 (SCN), which includes proteins involved in the transport of a wide range of molecules, including neurotransmitters.

SLC6A9 is a transmembrane protein that is composed of an N-terminal cytoplasmic domain, a transmembrane segment, and an C-terminal cytoplasmic domain. The N-terminal domain is involved in the formation of an ion channel that allows for the transport of neurotransmitters across the membrane. The transmembrane segment is responsible for the stability of the ion channel and the regulation of neurotransmitter transport. The C-terminal domain is involved in the regulation of the ion channel and in the formation of a complex with other proteins involved in neurotransmitter transport.

SLC6A9 has been shown to be involved in the transport of a variety of neurotransmitters, including GABA, glutamate, and dopamine. GABA is an inhibitory neurotransmitter that is involved in a wide range of physiological processes, including sleep, stress, and learning. Glutamate is a neurotransmitter that is involved in synaptic plasticity and learning. Dopamine is a neurotransmitter that is involved in motivation, pleasure, and movement.

SLC6A9 has also been shown to be involved in the regulation of intracellular neurotransmitter levels. For example, studies have shown that SLC6A9 can regulate the levels of GABA in brain cells and that it can also modulate the activity of GABA receptors. This suggests that SLC6A9 may play a role in the regulation of GABA-mediated signaling processes in the brain.

In addition to its involvement in neurotransmitter transport and regulation, SLC6A9 has also been shown to be involved in the regulation of intracellular signaling pathways. For example, studies have shown that SLC6A9 can interact with the protein Pyruvate Carrier (PyR) and that this interaction may be involved in the regulation of intracellular signaling pathways.

Given the involvement of SLC6A9 in neurotransmitter transport and regulation, it is a potential drug target for the treatment of a wide range of neuropsychiatric and neurological disorders. For example, SLC6A9 has been shown to be involved in the regulation of GABA levels and has been linked to the treatment of insomnia and other sleep disorders. Additionally, SLC6A9 has been shown to be involved in the regulation of intracellular signaling pathways and has been linked to the regulation of a variety of cellular processes, including cell survival, migration, and invasion. This suggests that SLC6A9 may be a useful biomarker for the evaluation of the efficacy of potential therapeutic compounds.

In conclusion, SLC6A9 is a transmembrane protein that is involved in the transport and regulation of neurotransmitters. Its involvement in a wide range of physiological processes makes it a potential drug target for the treatment of a variety of neuropsychiatric and neurological disorders. Further research is needed to fully understand the role of SLC6A9 in neurotransmission and to develop effective therapies based on this protein.

Protein Name: Solute Carrier Family 6 Member 9

Functions: Sodium- and chloride-dependent glycine transporter (PubMed:8183239). Essential for regulating glycine concentrations at inhibitory glycinergic synapses

The "SLC6A9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC6A9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets